355818-98-3

Basic information

• Product Name: 6-BOC-3-NITRO-7,8-DIHYDRO-5H-[1,6]NAPHTHYRIDINE
• Synonyms: 6-BOC-3-NITRO-7,8-DIHYDRO-5H-[1,6]NAPHTHYRIDINE;tert-Butyl 3-nitro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate
• CAS NO: 355818-98-3
• Molecular Formula: C13H17N3O4
• Molecular Weight: 279.3
• Mol File: 355818-98-3.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 6-BOC-3-NITRO-7,8-DIHYDRO-5H-[1,6]NAPHTHYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BOC-3-NITRO-7,8-DIHYDRO-5H-[1,6]NAPHTHYRIDINE(355818-98-3)
• EPA Substance Registry System: 6-BOC-3-NITRO-7,8-DIHYDRO-5H-[1,6]NAPHTHYRIDINE(355818-98-3)

Safety Data

• Hazardous Substances Data: 355818-98-3(Hazardous Substances Data)

Usage

General Description

6-BOC-3-NITRO-7,8-DIHYDRO-5H-[1,6]NAPHTHYRIDINE is a chemical compound that belongs to the class of naphthyridine derivatives. It is a nitro-substituted compound with a BOC (tert-butoxycarbonyl) protecting group. 6-BOC-3-NITRO-7,8-DIHYDRO-5H-[1,6]NAPHTHYRIDINE has potential applications in medicinal chemistry, particularly in the development of pharmaceuticals and agrochemicals. The presence of the nitro group makes it a potential precursor for the synthesis of various functionalized naphthyridines, which have been studied for their biological activities and pharmacological properties. Additionally, the BOC protecting group makes the compound suitable for use in organic synthesis and as an intermediate in the production of other complex molecules.

Upstream product

• 14150-94-8 3,5-dinitro-1-methyl-2-pyridone 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 785774-74-5 5,6,7,8-tetrahydro-1,6-naphthyridin-3-ol 
• 1184950-48-8 3-bromo-6-(tert-butoxycarbonyl)-5,6,7,8-tetrahydro-1,6-naphthyridine 
• 53454-30-1 3-Amino-1.6-naphthyridin 
• 123792-68-7 5,6,7,8-tetrahydro-3-nitro-1,6-naphthyridine 
• 355819-02-2 tert-butyl 3-amino-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carboxylate 

Relevant articles and documents

COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY

Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.

RESORCINOL DERIVATIVE AS HSP90 INHIBITOR

The present invention relates to a compound represented by formula (I) of a resorcinol derivative as an HSP90 inhibitor or pharmaceutically accepted salts thereof. The compound in the present invention has the activity of inhibiting heat shock protein HSP90. Therefore, the compound in the present invention is used to treat proliferative diseases such as cancer and neurodegenerative diseases. The present invention further provides the compounds and preparation methods for pharmaceutical compositions comprising the compounds, a method for treating diseases, and pharmaceutical compositions comprising the compounds.

Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists

SCH 58261 is a reported adenosine A2A receptor antagonist which is active in rat in vivo models of Parkinson's Disease upon ip administration. However, it has poor selectivity versus the A1 receptor and does not demonstrate oral activity. Quinoline analogs have improved upon the selectivity and pharmacokinetics of SCH 58261, but were difficult to handle due to poor aqueous solubility. We report the design and synthesis of fused heterocyclic analogs of SCH 58261 with aqueous solubility as well as improved A2A receptor binding selectivity and pharmacokinetic properties. In particular, the tetrahydronaphthyridine 4s has excellent A2A receptor in vitro binding affinity and selectivity, is active orally in a rat in vivo model of Parkinson's Disease, and has aqueous solubility of 100 μM at physiological pH.